clinical trial · NCT04963231
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Genetic ObesitySetmelanotidePlacebo
brief summary
The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.
started
Nov 30, 2021
primary completion
Aug 4, 2023
completion
Sep 30, 2024
last updated
Jul 2, 2025
official title
A 2-Stage (Open-Label Followed by Randomized Double-Blind, Placebo-Controlled Stage), Phase 2 Trial of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol